Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On February 19, Travere Therapeutics Inc. (NASDAQ:TVTX) released the fourth ...

Travere Therapeutics (TVTX) came out with quarterly earnings of $0.03 per share, in line with the Zacks Consensus Estimate . This compares to a loss of $0.73 per share a year ago. These figures are ...

Revenue: Fourth-quarter net product sales of $126.6 million; full-year 2025 net product sales of $410.5 million. Filspari Sales: Fourth-quarter net product sales of $103.3 million; full-year 2025 net ...

For the quarter ended December 2025, Travere Therapeutics (TVTX) reported revenue of $129.69 million, up 73.4% over the same period last year. EPS came in at $0.03, compared to -$0.73 in the year-ago ...

Travere also resumed enrollment in its pivotal Phase 3 HARMONY study of pegtibatinase for classical homocystinuria. The company ended the year with $322.8 million in cash, cash equivalents, and ...

Travere Therapeutics, Inc. today reported its fourth quarter and full year 2025 financial results and provided a corporate update. “2025 marked a year of meaningful advancement for Travere, ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Travere Therapeutics, Inc. (TVTX) on Thursday reported fourth-quarter profit of $2.7 million. The San Diego-based company said it had net income of 3 cents per share.

SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc. (TVTX) today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the close of the ...